霉酚酸酯与安慰剂治疗系统性硬化相关间质性肺病的比较
本研究比较霉酚酸酯(MMF)与安慰剂治疗系统性硬化(SSc)相关间质性肺病(ILD)的疗效,纳入SLS I安慰剂组(n=79)和SLS II的MMF组(n=69)。校正基线疾病严重程度后,MMF治疗与2年内用力肺活量(FVC)%、弥散功能(DLco)%、改良Rodnan皮肤厚度评分(MRSS)及呼吸困难改善相关。
要点
- MMF治疗与2年内FVC%预测值改善相关(P<0.0001)。
- MMF治疗与2年内DLco%预测值、MRSS及呼吸困难改善相关。
- 结果支持MMF用于SSc相关ILD的治疗。
核心结论
- 尽管跨试验比较存在固有局限,MMF治疗与生理学结局和呼吸困难改善相关,即使校正基线疾病严重程度后仍显著。
研究设计与样本
- 研究纳入SLS I的安慰剂组(n=79)和SLS II的MMF组(n=69)参与者进行比较。
- SLS I将参与者随机分配至口服环磷酰胺(CYC)或安慰剂治疗1年;SLS II将参与者随机分配至MMF治疗2年或口服CYC治疗1年后续安慰剂1年。
- 采用联合模型评估治疗对2年内结局变化的影响。
主要发现
- 基线时两组性别比例、疾病病程、SSc亚型、皮肤病变范围和FVC%预测值相似。
- MMF组年龄稍大(均值±标准差52.6±9.7岁 vs 48.1±12.4岁;P=0.0152)。
- MMF组基线DLco%预测值较高(均值±标准差54.0±11.1 vs 46.2±13.3;P=0.0002)。
- 校正基线疾病严重程度后,MMF与安慰剂相比,2年内FVC%预测值改善(P<0.0001)、DLco%预测值改善(P<0.0001)、MRSS改善(P<0.0001)、呼吸困难改善(P=0.0112)。
关键数值与推荐
- 主要结局为FVC%预测值;关键次要结局包括DLco%预测值、MRSS和呼吸困难。
- MMF与安慰剂比较,FVC%预测值改善P<0.0001。
- MMF与安慰剂比较,DLco%预测值改善P<0.0001。
- MMF与安慰剂比较,MRSS改善P<0.0001。
- MMF与安慰剂比较,呼吸困难改善P=0.0112。
临床怎么用
- 对于SSc相关ILD患者,MMF治疗可考虑用于改善肺功能、皮肤厚度和呼吸困难。
局限性
- 比较来自不同试验的参与者存在固有局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)-related interstitial lung disease (ILD). METHODS: We included participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II. SLS I randomized participants to receive either oral cyclophosphamide (CYC) or placebo for 1 year, while SLS II randomized participants to receive either MMF for 2 years or oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and SLS II were nearly identical. The primary outcome was % predicted forced vital capacity (FVC), and key secondary outcomes included % predicted diffusing capacity for carbon monoxide (DLco), the modified Rodnan skin thickness score (MRSS), and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years. RESULTS: At baseline, the MMF-treated group in SLS II (n = 69) and the placebo-treated group in SLS I (n = 79) had similar percentages of men and women and similar disease duration, SSc subtype, extent of skin disease, and % predicted FVC. MMF-treated patients in SLS II were slightly older (mean ± SD age 52.6 ± 9.7 years versus 48.1 ± 12.4 years; P = 0.0152) and had higher % predicted DLco (mean ± SD 54.0 ± 11.1 versus 46.2 ± 13.3; P = 0.0002) than placebo-treated patients in SLS I. After adjustment for baseline disease severity, treatment with MMF in comparison with placebo was associated with improved % predicted FVC (P < 0.0001), % predicted DLco (P < 0.0001), MRSS (P < 0.0001), and dyspnea (P = 0.0112) over 2 years. CONCLUSION: Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc-related ILD.
引用
- Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017. PMID: 28376288. doi:10.1002/art.40114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。